Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Oct;11(10):E174-E177.
doi: 10.21037/jtd.2019.09.44.

Driving the discussion about the greater propensity for doing better with neoadjuvant chemotherapy for non-small cell lung cancer

Abigail K Zamora  1 , Anthony W Kim  1
Affiliations
Editorial

Driving the discussion about the greater propensity for doing better with neoadjuvant chemotherapy for non-small cell lung cancer

Abigail K Zamora et al. J Thorac Dis. 2019 Oct.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
A hypothetical model demonstrating the impact of variable compliance associated with timing of systemic chemotherapy administration. Based upon the propensity-matched data, 13–15% of patients with cT24N01 will not receive the benefit of chemotherapy if it is administered postoperatively. (A) Demonstrates the differences in chemotherapy compliance between the NC and AC cohorts according to the propensity-matched numbers reported; (B) demonstrates the increased number of patients unable to undergo chemotherapy when all patients previously undergoing NC are relegated to the AC cohort in a hypothetical model that uses the same proportions as the AC group in the propensity-matched cohort applied to the entire unmatched cohort. In this hypothetical model using the entire cohort of 330 patients, an additional 31 patients would not undergo systemic therapy if AC was the only option; whereas, this difference was 16 patients between the propensity-matched cohorts. NC, neoadjuvant chemotherapy; AC, adjuvant chemotherapy.
See this image and copyright information in PMC

Comment on

References

    1. Brandt WS, Yan W, Zhou J, et al. Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non-small cell lung cancer: a propensity-matched analysis. J Thorac Cardiovasc Surg 2019;157:743-53.e3. 10.1016/j.jtcvs.2018.09.098 - DOI - PMC - PubMed
    1. National Comprehensive Cancer Network. Non-small cell lung cancer (Version 5.2019). Accessed July 1, 2019. Available online: https://www.nccn.org/professionals/physician_gls/PDF/nscl.pdf
    1. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9. 10.1200/JCO.2007.13.9030 - DOI - PubMed
    1. Berry MF, Coleman BK, Curtis LH, et al. Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients. Ann Surg Oncol 2015;22:642-8. 10.1245/s10434-014-4056-0 - DOI - PMC - PubMed
    1. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004;350:351-60. 10.1056/NEJMoa031644 - DOI - PubMed